Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
The latest update on Vivos Therapeutics centers on a trimmed fair value estimate, with the price target moving from about US$2.45 to roughly US$2.12 per share. This shift lines up with recent Street commentary that has paired cautious or Neutral ratings with lower targets, as analysts weigh balance sheet concerns and potential equity dilution against ongoing clinical and commercial efforts. Read on to see what is driving these price target resets and how to track the evolving narrative around Vivos Therapeutics.
What Wall Street Has Been Saying 🐂 Bullish Takeaways
Analysts covering Vivos Therapeutics continue to follow the story closely, which keeps a spotlight on the company’s clinical and commercial execution even as targets move lower.
Price targets from firms such as Alliance Global and H.C. Wainwright still imply some value for the equity, which signals that coverage firms see potential if balance sheet issues are addressed.
🐻 Bearish Takeaways
Alliance Global cut its Vivos Therapeutics price target to US$0.75 from US$1.75 and reiterated a Neutral rating, flagging that the balance sheet needs “significant reinforcement,” which the firm links to elevated financial risk.
The Alliance Global update explicitly ties its lower target to increased expected equity dilution, highlighting concerns that any future capital raising could weigh on existing shareholders.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
NasdaqCM:VVOS 1-Year Stock Price Chart
We’ve flagged 4 risks for Vivos Therapeutics. See which could impact your investment.
How This Changes the Fair Value For Vivos Therapeutics
Fair value trimmed from about US$2.45 to roughly US$2.12 per share.
Revenue growth assumption adjusted from about 33.22% to roughly 33.42%.
Net profit margin moved from about 6.10% to around 6.12%.
Future P/E reduced from roughly 19.36x to about 16.67x.
Discount rate revised from 9.47% to about 9.64%.
Never Miss an Update: Follow The Narrative
Narratives connect Vivos Therapeutics’ business story to the assumptions behind earnings forecasts and fair value estimates. They update as new clinical results, financing moves, and regulatory news come through, so you can see how the story is evolving in real time.
Head over to the Simply Wall St Community and follow the Narrative on Vivos Therapeutics to stay up to date on:
How FDA clearance for Vivos devices in severe obstructive sleep apnea as well as patient preference for non invasive options are shaping the addressable market for its oral appliances and related services.
The shift from legacy VIP enrollment revenue to recurring, services driven sleep care models, including Sleep Optimization teams, Sleep Center of Nevada integration, and collaborations such as AIM Florida.
Key risks around ongoing operating losses, dependence on higher cost financing, execution on acquisitions and capacity ramp up, and pressure from competitors and reimbursement trends that could affect margins and growth.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include VVOS.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com